Gilead Sciences, Inc. (GILD) Stock Rating Reaffirmed by Berenberg Bank
Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “buy” rating restated by investment analysts at Berenberg Bank in a note issued to investors on Sunday. They presently have a $86.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $79.00. Berenberg Bank’s target price would suggest a potential upside of 19.26% from the stock’s previous close.
Other equities analysts have also issued reports about the stock. Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 target price for the company in a research note on Tuesday, May 2nd. BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Barclays PLC reaffirmed an “overweight” rating and issued a $85.00 target price (down from $90.00) on shares of Gilead Sciences in a research note on Sunday, April 23rd. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 target price for the company in a research note on Monday, June 26th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and issued a $79.00 target price on shares of Gilead Sciences in a research note on Monday, May 15th. Eleven research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $80.64.
Shares of Gilead Sciences (NASDAQ GILD) traded down 0.32% during mid-day trading on Friday, hitting $72.11. The stock had a trading volume of 6,052,601 shares. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $82.10. The stock’s 50-day moving average price is $72.61 and its 200-day moving average price is $68.83. The stock has a market capitalization of $94.17 billion, a price-to-earnings ratio of 7.83 and a beta of 1.21.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. During the same quarter in the previous year, the business earned $3.08 EPS. The firm’s revenue was down 8.2% on a year-over-year basis. On average, equities analysts anticipate that Gilead Sciences will post $8.75 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Stock Rating Reaffirmed by Berenberg Bank” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/08/20/gilead-sciences-inc-gild-stock-rating-reaffirmed-by-berenberg-bank.html.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the sale, the insider now owns 3,199,969 shares in the company, valued at $227,197,799. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the sale, the executive vice president now owns 102,988 shares in the company, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. Insiders sold 206,666 shares of company stock worth $15,223,184 in the last 90 days. Company insiders own 1.30% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. S&CO Inc. increased its position in Gilead Sciences by 1.5% in the first quarter. S&CO Inc. now owns 6,275 shares of the biopharmaceutical company’s stock valued at $426,000 after buying an additional 95 shares during the last quarter. Raymond James Trust N.A. increased its position in Gilead Sciences by 14.5% in the first quarter. Raymond James Trust N.A. now owns 25,886 shares of the biopharmaceutical company’s stock valued at $1,758,000 after buying an additional 3,273 shares during the last quarter. Denali Advisors LLC increased its position in Gilead Sciences by 20.5% in the first quarter. Denali Advisors LLC now owns 150,877 shares of the biopharmaceutical company’s stock valued at $10,248,000 after buying an additional 25,664 shares during the last quarter. Trust Co increased its position in Gilead Sciences by 21.4% in the fourth quarter. Trust Co now owns 32,310 shares of the biopharmaceutical company’s stock valued at $2,314,000 after buying an additional 5,699 shares during the last quarter. Finally, Acropolis Investment Management LLC increased its position in Gilead Sciences by 0.7% in the first quarter. Acropolis Investment Management LLC now owns 16,475 shares of the biopharmaceutical company’s stock valued at $1,119,000 after buying an additional 120 shares during the last quarter. Hedge funds and other institutional investors own 74.02% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.